Study Finds That Patients with Cancer and a Suppressed Immune System Are at High Risk for Severe COVID if Treated with Systemic Drug Therapies
Dana-Farber Cancer InstitutePatients with cancer and a weakened immune system who are treated with immunotherapies tend to fare far worse from COVID-19 than those who haven't received such therapies in the three months before their COVID diagnosis, show findings in a new study by researchers at Dana-Farber Cancer Institute, and across the U.S., Canada, and Mexico. Researchers found worse outcomes in both the disease itself as well as the fierce immune response that sometimes accompanies it.